Clinical Trials
4 trialsNCT01434472 2021-07-20
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00689169 2018-03-07
ZBEAM2
Lymphoma Study Association
Phase 2 Completed
NCT00220285 2014-12-30
Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma
Bayer
Phase 2 Completed
NCT00138086 2006-09-08
Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma
Lymphoma Study Association
Phase 2 Completed